Bicycle Therapeutics (NASDAQ:BCYC) Receives Equal Weight Rating from Stephens

Stephens reissued their equal weight rating on shares of Bicycle Therapeutics (NASDAQ:BCYC) in a research report released on Wednesday,Benzinga reports. Stephens currently has a $15.00 price target on the stock.

Several other analysts also recently weighed in on BCYC. HC Wainwright restated a “buy” rating and set a $33.00 target price on shares of Bicycle Therapeutics in a research note on Monday, January 13th. Needham & Company LLC restated a “buy” rating and set a $32.00 price objective on shares of Bicycle Therapeutics in a research note on Monday, January 13th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $35.00 target price on shares of Bicycle Therapeutics in a research report on Friday, November 1st. JMP Securities decreased their price target on shares of Bicycle Therapeutics from $32.00 to $26.00 and set a “market outperform” rating for the company in a research report on Wednesday, December 18th. Finally, B. Riley cut their price target on shares of Bicycle Therapeutics from $28.00 to $17.00 and set a “neutral” rating on the stock in a report on Friday, December 13th. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $33.25.

Bicycle Therapeutics Stock Performance

BCYC stock opened at $12.98 on Wednesday. The stock has a 50-day simple moving average of $16.56 and a 200-day simple moving average of $21.23. The firm has a market cap of $896.27 million, a P/E ratio of -3.95 and a beta of 0.92. Bicycle Therapeutics has a 1 year low of $12.17 and a 1 year high of $28.67.

Bicycle Therapeutics (NASDAQ:BCYC) last posted its quarterly earnings data on Thursday, October 31st. The company reported ($0.74) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.04. The company had revenue of $2.68 million for the quarter, compared to analyst estimates of $6.82 million. Bicycle Therapeutics had a negative net margin of 450.64% and a negative return on equity of 27.35%. The business’s quarterly revenue was down 50.0% on a year-over-year basis. During the same quarter last year, the firm posted ($1.26) earnings per share. On average, equities research analysts predict that Bicycle Therapeutics will post -3.05 EPS for the current year.

Insider Buying and Selling

In other Bicycle Therapeutics news, CAO Travis Alvin Thompson sold 6,256 shares of the firm’s stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $25.11, for a total value of $157,088.16. Following the transaction, the chief accounting officer now owns 19,241 shares of the company’s stock, valued at $483,141.51. This trade represents a 24.54 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Bros. Advisors Lp Baker bought 985,397 shares of the firm’s stock in a transaction on Friday, December 13th. The stock was bought at an average price of $13.76 per share, with a total value of $13,559,062.72. Following the completion of the purchase, the director now owns 9,537,643 shares of the company’s stock, valued at $131,237,967.68. This trade represents a 11.52 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold 33,933 shares of company stock worth $549,501 over the last ninety days. 8.50% of the stock is owned by insiders.

Institutional Investors Weigh In On Bicycle Therapeutics

A number of hedge funds have recently added to or reduced their stakes in BCYC. GAMMA Investing LLC increased its holdings in shares of Bicycle Therapeutics by 105.1% in the 3rd quarter. GAMMA Investing LLC now owns 2,026 shares of the company’s stock worth $46,000 after acquiring an additional 1,038 shares during the period. L & S Advisors Inc increased its stake in shares of Bicycle Therapeutics by 2.4% in the third quarter. L & S Advisors Inc now owns 59,735 shares of the company’s stock valued at $1,352,000 after purchasing an additional 1,400 shares during the period. Assetmark Inc. bought a new stake in shares of Bicycle Therapeutics during the third quarter valued at approximately $34,000. JPMorgan Chase & Co. boosted its position in shares of Bicycle Therapeutics by 26.8% during the third quarter. JPMorgan Chase & Co. now owns 8,424 shares of the company’s stock worth $191,000 after buying an additional 1,782 shares during the period. Finally, China Universal Asset Management Co. Ltd. grew its holdings in Bicycle Therapeutics by 30.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 9,329 shares of the company’s stock worth $131,000 after buying an additional 2,191 shares in the last quarter. 86.15% of the stock is currently owned by institutional investors.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.